Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 9/20 | 0.59 |
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13870307 | 0.95 | ALDH1A1 (0.55) | ALDH1A1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL1262258 | 0.85 | TSHR (0.52) | ALDH1A1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL2664776 | 0.81 | GCK (0.60) | ALDH1A1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL12742436 | 0.80 | SMN1; SMN2 (0.66) | ALDH1A1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL1263061 | 0.79 | CDK2 (0.52) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL1262635 | 0.79 | TSHR (0.46) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL2664785 | 0.79 | GCK (0.60) | ALDH1A1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL1262488 | 0.78 | CDK2 (0.57) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL1262307 | 0.78 | TSHR (0.46) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL2664772 | 0.77 | GCK (0.69) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | ALDH1A1 1137/4885RAB9A 3175/4885NPC1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.